TNP-2092

DRUG2 trials

Sponsors

TenNor Therapeutics Limited

Conditions

Gram-Positive Bacterial InfectionsProsthetic Joint InfectionSkin and Subcutaneous Tissue Bacterial Infections

Phase 1

Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty

CompletedNCT04294862

TenNor Therapeutics LimitedProsthetic Joint Infection

Start: 2021-03-01End: 2022-06-29Updated: 2022-10-19

Phase 2

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection

CompletedNCT03964493

TenNor Therapeutics LimitedGram-Positive Bacterial Infections, Skin and Subcutaneous Tissue Bacterial Infections

Start: 2019-04-20End: 2020-09-28Updated: 2023-12-01

Related Papers

P-1090. Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial

Open Forum Infectious Diseases2025-01-291 citations

P-1116. Distribution of Rifaquizinone in Bone, Synovial Fluid and Plasma: A Phase 1 Trial in Patients Undergoing Total Hip or Knee Arthroplasty

Open Forum Infectious Diseases2025-01-291 citations